How Topoisomerase II Inhibitors Affect NF-κB Activity
Author Information
Author(s): Kirsteen J. Campbell, John M. O'Shea, Neil D. Perkins
Primary Institution: University of Dundee
Hypothesis
What specific features of topoisomerase II inhibitors are required to induce NF-κB DNA-binding and transcriptional repression in U-2 OS cells?
Conclusion
Topoisomerase II inhibitors induce NF-κB DNA-binding and transcriptional repression primarily through their ability to intercalate into DNA, rather than through topoisomerase II inhibition or oxygen free radical production.
Supporting Evidence
- Mitoxantrone, which does not produce free radicals, still induced NF-κB DNA-binding.
- Aclarubicin, which intercalates with DNA, also induced NF-κB DNA-binding.
- ICRF-193, which inhibits topoisomerase II but does not intercalate, did not induce NF-κB DNA-binding.
Takeaway
Some cancer drugs can change how a protein called NF-κB works. This study found that certain drugs work by getting inside DNA, which can stop the cell from making proteins that help it survive.
Methodology
The study used U-2 OS osteosarcoma cells to investigate the effects of various topoisomerase II inhibitors on NF-κB DNA-binding and transcriptional activity.
Limitations
Results may vary in other cell lines, and caution should be taken when extrapolating findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website